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ABSTRACT Tumor necrosis factor (TNF) mediates a
wide variety of disease states including septic shock, acute and
chronic inflammation, and cachexia. Recently, a multivalent
guanylhydrazone (CNI-1493) developed as an inhibitor of
macrophage activation was shown to suppress TNF produc-
tion and protect against tissue inflammation and endotoxin
lethality [Bianchi, M., Ulrich, P., Bloom, O., Meistrell, M.,
Zimmerman, G.A., Schmidtmayerova, H., Bukrinsky, M.,
Donnelley, T., Bucala, R., Sherry, B., Manogue, K. R., Torto-
lani, A. J., Cerami, A. & Tracey, K. J. (1995) Mol. Med. 1,
254-266, and Bianchi, M., Bloom, O., Raabe, T., Cohen, P. S.,
Chesney, J., Sherry, B., Schmidtmayerova, H., Zhang, X.,
Bukrinsky, M., Ulrich, P., Cerami, A. & Tracey, J. (1996) J.
Exp. Med., in press]. We have now elucidated the mechanism
by which CNI-1493 inhibits macrophage TNF synthesis and
show here that it acts through suppression ofTNF translation
efficiency. CNI-1493 blocked neither the lipopolysaccharide(LPS)-induced increases in the expression ofTNF mRNA nor
the translocation of nuclear factor NF-KB to the nucleus in
macrophages activated by 15 min of LPS stimulation, indi-
cating that CNI-1493 does not interfere with early NF-KB-
mediated transcriptional regulation of TNF. However, syn-
thesis of the 26-kDa membrane form of TNF was effectively
blocked by CNI-1493. Further evidence for the translational
suppression of TNF is given by experiments using chloram-
phenicol acetyltransferase (CAT) constructs containing el-
ements of the TNF gene that are involved in TNF transla-
tional regulation. Both the 5' and 3' untranslated regions of
the TNF gene were required to elicit maximal translational
suppression by CNI-1493. Identification of the molecular
target through which CNI-1493 inhibits TNF translation
should provide insight into the regulation of macrophage
activation and mechanisms of inflammation.
Following the activation of monocytes and macrophages, the
rapid production of proinflammatory cytokines [such as tumor
necrosis factor (TNF), interleukins 1 and 6 (IL-1 and IL-6) and
others] mediates a wide variety of pathologic states, including
lethal shock and tissue injury, acute and chronic inflammation,
and cachexia (1). We recently described a tetravalent guanyl-
hydrazone compound (CNI-1493) that suppressed lipopoly-
saccharide (LPS)-stimulated macrophage synthesis of proin-
flammatory cytokines [TNF, IL-1, IL-6, macrophage inflam-
matory proteins la and 1,3 (MIP-la and MIP-1l3], inhibited
the synthesis of inducible nitric oxide synthase (iNOS), and
protected against lethal endotoxemia and carrageenan-
induced inflammation in mice (2, 3). Previous evidence indi-
cates that these macrophage-suppressive effects were selective.
For instance, concentrations of CNI-1493 that completely
suppressed TNF protein synthesis did not suppress total
cellular RNA transcription as measured by incorporation of
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labeled uridine into total RNA and did not suppress total
cellular protein synthesis as measured by incorporation of
labeled methionine into total protein (3). Moreover, these
concentrations of CNI-1493 did not inhibit enhanced expres-
sion of major histocompatibility complex (MHC) class II
antigens mediated by y interferon (IFN-'y) (3). By contrast
with glucocorticoids, another class of inhibitors that suppresses
proinflammatory cytokine production, CNI-1493 retained its
TNF-suppressive effects even in the presence of IFN-y.
TNF synthesis in monocytes/macrophages is stimulated by
LPS and other invasive stimuli (1). This production is mediated
by increases in the transcription and translation of the TNF
gene (4). Recent evidence suggests that discrete signal trans-
duction pathways regulate the transcriptional and translational
regulatory events (Fig. 1). The p38 MAP kinase signal trans-
duction pathway, whose intermediates include cdc42, MEKK,
MKK3/MKK4, and p38 MAP kinase (5-7), has been impli-
cated in the enhancement of TNF translation efficiency after
LPS stimulation (8-10). Transcriptional activation is mediated
by pathways culminating in nuclear translocation of the tran-
scriptional regulator NF-KB. In these cascades, LPS stimulates
the release of I-KB from cytoplasmic NF-KB, resulting in
translocation of NF-KB from the cytoplasm to the nucleus,
where it binds KB consensus binding sites in the promoters of
target genes including TNF and genes of other proinflamma-
tory cytokines (11-13). In the present investigation, we deter-
mine the mechanism by which CNI-1493 suppresses TNF
protein synthesis. The results now indicate that CNI-1493 acts
by inhibiting TNF translational efficiency and not by inhibiting
the nuclear translocation of NF-KB in LPS-stimulated macro-
phages.
MATERIALS AND METHODS
Cell Isolation and Culture. For studies of human mono-
cytes, buffy coats were obtained by elutriation from normal
individual donors to the Long Island Blood Bank Services.
Peripheral blood mononuclear cells (PBMCs) were isolated
by density-gradient centrifugation through Ficoll/Hypaque(Pharmacia); typically one preparation yielded 200 x 106
adherent cells. These cells were cultured in 100-mm plates at
2 x 106 cells per plate in 5 ml of RPMI 1640 medium
containing 10% (vol/vol) normal heat-inactivated human
serum, antibiotics, and L-glutamine. Cells were allowed to
adhere overnight in the presence of 5% CO2 in a humidified
incubator at 37°C. Nonadherent cells were washed away
twice with phosphate-buffered saline (PBS), and adherent
cells (monocytes) were then treated with CNI-1493 at 1 /iM
Abbreviations: PBMC, peripheral blood mononuclear cell; CMV,
cytomegalovirus; TNF, tumor necrosis factor; LPS, lipopolysaccha-
ride; CAT, chloramphenicol acetyltransferase; IL-1 and IL-6, inter-
leukins 1 and 6; MAP kinase, mitogen-activated kinase; MIP, mac-
rophage inflammatory protein; iNOS, inducible nitric oxide synthase;
IFN-y, y interferon; MHC, major histocompatibility complex; UTR,
untranslated region.
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FIG. 1. Schematic illustration of putative signal transduction path-
ways regulating the macrophage activation-mediated production of
TNF. MAPK, mitogen-activated protein (MAP) kinase.
for various periods of time, followed by stimulation with LPS(Escherichia coli 0111:B4, 100 ng/ml; Sigma) for either 2 hr(for RNA studies) or 4 hr (for protein studies). The murine
macrophage-like RAW 264.7 cells [obtained from the Amer-
ican Type Culture Collection (ATCC), Rockville, MD] were
maintained in RPMI 1640 medium containing 10% fetal calf
serum (FCS), antibiotics, and L-glutamine. Cells were al-
lowed to adhere for 4 hr prior to use in experiments.
Total RNA Isolation and Quantitation of TNF mRNA
Levels. Total RNA was prepared from primary PBMCs treated
with LPS at 100 ng/ml with or without 1 ,uM CNI-1493 and/or
5 ptg of actinomycin D per ml for 0, 20, or 40 min by using the
RNAzol B reagent (Tel-Test, Friendswood, TX) per the
manufacturer's instructions. Competitive reverse transcription(RT)-PCR methods were used to quantitate TNF mRNA
levels (14). Briefly, one set of oligonucleotide primers was used
to amplify both endogenous TNF cDNA and exogenously
added artificial TNF-MIMIC DNA of known concentration.
MIMIC template was constructed with the use of a PCR-
MIMIC construction kit (Clontech) following the manufac-
turer's instructions. Primer pairs used for MIMIC synthesis
were 5'-ACTGAAAGCATGATCCGGGACCGCAAGT-
GAAATCTCCTCCG-3' and 5'-TCACAGGGCAATGATC-
CCAAATCTGTCAATGCAGTTGTGAG-3'. Primers used
for RT-PCR of both TNF-MIMIC and endogenous TNF
mRNA were: 5'-ACTGAAAGCATGATCCGGGAC-3' (span-
ning TNF base pairs 92-112) and 5'-TCACAGGGC-AATG-
ATCCCAAA-3' (spanning TNF base pairs 766-787), which
yielded a 695-bp fragment from endogenous TNF mRNA and a
450-bp TNF-MIMIC fragment (15). RT-PCR was per-
formed by using the Perkin-Elmer RT-PCR kit as per the
manufacturer's instructions with the following modifica-
tions: (i) 0.35 /g of RNA was used per reaction, (ii) the RT
reaction was primed with random hexamers, (iii) the PCR
reaction was amplified for 30 cycles, and the (iv) PCR
reaction was adjusted to contain 2.5 mg of MgCl2 per ml. The
PCR cycle consisted of 95°C for 15 sec, 55°C for 30 sec, and
65°C for 60 sec. After the final amplification, the reaction
was elongated for 7 min at 72°C. Twenty microliters of each
reaction mixture was separated by electrophoresis by using
1.5% agarose gels, followed by staining with ethidium bro-
mide. The quantity of TNF cDNA in a given reaction sample
was measured by extrapolating from serial dilutions of
TNF-MIMIC in the same reaction.
Electrophoretic Mobility Shift Assay. RAW 264.7 cells were
treated with CNI-1493 at various concentrations and stimu-
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lated with 100 ng of LPS per ml for 15 min. Cells were then
rinsed in ice-cold PBS and harvested. Extracts were prepared
essentially as described (16) and incubated with 32P-labeled
oligodeoxynucleotides corresponding to the NF-KB consensus
binding site (Promega). Binding reactions and electrophoresis
were performed as described (16).
TNF Pulse Labeling. Newly synthesized proteins were
radiolabeled by using a modified version of previously
described methods (17, 18). Briefly, human PBMCs isolated
by elutriation and purified by adherence were incubated
overnight in Dulbecco's modified Eagle's medium contain-
ing 10% FCS, antibiotics, and L-glutamine without methio-
nine and were treated with CNI-1493 in concentrations
shown. After 1 hr, the medium was replaced with fresh
methionine-free medium containing 0.2 mCi of [35S]methi-
onine (NEN) and 100 ng of LPS per ml for 1 hr. The
pulse-labeling period was terminated by removing the cul-
ture medium, washing the cells twice with PBS, and adding
methionine-containing medium. Cells were lysed in buffer[50 mM Tris-HCl, pH 7.4/100 mM NaCl/1% Triton X-100/5
mM EDTA/0.02% sodium azide/100 ,M phenylmethylsul-
fonyl fluoride (PMSF)/1 uLM pepstatin]; 50 /l of lOx lysis
buffer was added per 500-/al supernatants. Cell lysates were
immunoprecipitated with polyclonal rabbit anti-human TNF(from Barbara Sherry, Picower Institute), collected over
protein A-agarose beads, and analyzed by SDS/PAGE elec-
trophoresis and autoradiography.
Chloramphenicol Acetyltransferase (CAT) Assay. Plasmid
constructs containing the CAT gene and either elements of the
human TNF 3' untranslated region downstream (3' UTR), the
5' untranslated region (5' UTR), both 5' and 3' fragments (5'
UTR-3' UTR), or the cytomegalovirus (CMV) promoter were
generous gifts of Bruce Beutler (University of Texas South-
western Medical Center, Dallas). Through use of these re-
porter constructs, both the 3' and 5' UTR regions of the TNF
gene have been shown to contribute to the regulation of TNF
biosynthesis at the translational level (19-21). CAT construct(2-10 /Lg of DNA) was cotransfected into RAW 264.7 cells
with 2 ,tg of plasmid pCH110 containing the 3-galactosidase
gene under the control of the simian virus 40 promoter(Pharmacia), which was included as an internal control for
transfection efficiency. Transfections were performed by a
calcium phosphate precipitation method (22). Cells were
washed 24 and 48 hr later with medium, treated with 1 /aM
CNI-1493 for 1 hr where indicated and then exposed to LPS at
1 ,ug/ml. After four hours, cell lysates were harvested for
determination of both 3-galactosidase and CAT activity. P-ga-
lactosidase activity was photometrically assayed by measuring
the conversion of o-nitrophenyl f3-D-galactopyranoside (23).
CAT assays were performed by using 25 unit equivalents of
3-galactosidase per TLC assay according to the method of
Gorman and others (24). CAT results were imaged and
quantitated on a phosphorimager (Packard Instantimager);
TLC plates were also exposed to Kodak XAR film. All
experiments were performed in triplicate.
RESULTS
CNI-1493 Does Not Suppress Increased Expression of
TNF mRNA. In agreement with previous results (2), we
found that addition of 1 /tM CNI-1493 to PBMCs suppressed
95% of secreted TNF protein measured by ELISA in super-
natants collected 4 hr after LPS stimulation (data not
shown). To evaluate whether CNI-1493 inhibited TNF via
suppression of transcriptional regulation, steady-state TNF
mRNA levels were measured in LPS-activated PBMCs by
using the method of quantitative RT-PCR. TNF mRNA was
observed to increase nearly one million-fold within 2 hr after
LPS activation (Fig. 2). Addition of CNI-1493 in quantities
that suppressed 95% of secreted TNF protein (1 /aM) in
Proc. Natl. Acad. Sci. USA 93 (1996) 3969
these experiments did not significantly reduce the increased
expression of TNF mRNA (Fig. 2). We observed a modest
reduction in peak steady-state level of TNF mRNA, which
was attributable to decreased TNF mRNA stability, mea-
sured by treating PBMCs with LPS and CNI-1493 in the
presence of actinomycin D (Fig. 2). Thus, these data give
evidence that the suppressive effect of CNI-1493 on TNF
protein production cannot be due to suppression of TNF
mRNA expression.
CNI-1493 Does Not Inhibit Nuclear Translocation of NF-KB
During Early Macrophage Activation. Because CNI-1493 did
not interfere with LPS-induced up-regulation of TNF mRNA,
these results predicted that CNI-1493 would not suppress the
early activation of NF-KB, a transcriptional activator of TNF
(13, 25, 26). Accordingly, the electrophoretic mobility-shift
assay was utilized to address this hypothesis. Addition of
CNI-1493 at concentrations that inhibit 50% and 95% of TNF
protein (0.5 and 1,M, respectively) did not inhibit the nuclear
translocation of NF-KB following LPS stimulation (Fig. 3).
Thus, CNI-1493 failed to inhibit the early NF-KB signal
transduction pathways activated within 15 min after LPS
treatment and allowed increased expression transcription of
TNF mRNA.
CNI-1493 Inhibits Synthesis of Membrane-Bound TNF
(26 kDa). To address directly CNI-1493 inhibition of TNF
protein translation, we used [35S]methionine labeling and
immunoprecipitation to determine the effect of CNI-1493 on
the translation of the 26-kDa membrane TNF prohormone
(17). CNI-1493 effectively suppressed the synthesis of the
26-kDa prohormone (Fig. 4). Because the 26-kDa prohor-
mone is the precursor to mature 17-kDa TNF, inhibition of
26-kDa protein translation thereby prevented appearance of
the 17-kDa form as well (Fig. 4). Since LPS stimulation
normally increases the translational efficiency of the 26-kDa
TNF (17), these results indicate that CNI-1493 suppresses
TNF production by inhibiting the translational activation of
26-kDa TNF.
CNI-1493 Suppresses TNF Translation Through Both 5'
and 3' UTRs of TNF. It has previously been shown that
elements in both the 5' and the 3' UTRs of the TNF gene
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FIG. 3. Effect of CNI-1493 on LPS-induced NF-KB activation in
RAW 264.7 cells. RAW 264.7 cells were treated with CNI-1493 at
various concentrations for 1 hr as indicated. Cells were stimulated with
LPS at 100 ng/ml for 15 min. Whole-cell lysates were prepared and
analyzed for NF-KB binding activity as described in text.
contribute to the enhanced translational efficiency of TNF
mRNA in monocytes/macrophages after LPS stimulation (19,
20, 27). We used these same CAT plasmid constructs to
address whether the suppressive effect of CNI-1493 on TNF
protein translation depended on the presence of either or both
of these elements. In agreement with previous work (19, 20,
27), transfection ofRAW 264.7 cells with the 3' UTR, 5' UTR,
and 5' UTR-3' UTR construct suppressed expression of CAT
as compared with transfections with CMV-CAT constructs not
containing TNF elements (data not shown), and addition of
LPS significantly stimulated CAT reporter activity (Fig. 5).
Addition of 1 ,uM CNI-1493 suppressed CAT reporter bio-
synthesis in LPS-treated cells containing either the 5' UTR,
the 3' UTR, or the 5' UTR-3' UTR constructs (Fig. 5).
Average suppression of LPS-mediated CAT biosynthesis for
the different constructs we observed was: 5' UTR (24 + 2%,
n = 3), 3' UTR (24 + 17%, n = 3) and 5' UTR-3' UTR (74
± 10%, n = 2). Expression of CAT in CMV-CAT control
transfectants was detected under all conditions and was not
responsive to the addition of either LPS or CNI-1493 (data not
shown). Note that maximal suppression by CNI-1493 was
observed only when both elements were present, suggesting
that suppression ofTNF translation by CNI-1493 is dependent
upon synergy between the 5' UTR and 3' UTR elements of
TNF mRNA.
DISCUSSION
CNI-1493 is a potent inhibitor of monocyte/macrophage
TNF synthesis. The present data now give direct evidence
that pharmacological quantities of CNI-1493 inhibit the
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FIG. 2. Quantitation of steady-state TNF mRNA levels in human
PBMCs. Human PBMCs were harvested for total mRNA, and TNF
mRNA levels were quantitated by using competitive RT-PCR as
described in text. TNF mRNA was assayed in the unstimulated state
(-), after 2 hr of LPS treatment at 100 ng/ml (v) and after 1-hr
pretreatment with 1 ,tM CNI-1493 followed by 2 hr of LPS treatment(K). Half-life studies were performed by treating PBMCs as above
with addition of actinomycin D at 5 ,ug/ml prior to mRNA harvest.
Time points shown are after addition of LPS; actinomycin D was
added at 120 min. Data are expressed as the mean ± SD (n = 3
experiments); where error bars are not visible, they lie within the
symbol itself.
l7kDa-
FIG. 4. Inhibition of 26-kDa TNF protein synthesis by CNI-1493
in human PBMCs. Human PBMCs were incubated in the presence
(lanes 3 and 4) or absence (lanes 1 and 2) of 2.5 ,M CNI-1493 and
in the presence (lanes 2 and 4) or absence (lanes 1 and 3) of LPS and
[35S]methionine for 1 hr. Cell lysates were prepared and immuno-
precipitated with anti-TNF antisera and were analyzed by electro-
phoresis and autoradiography. The positions of the TNF immuno-
reactive bands are identified by their apparent molecular weights on
the left.
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FIG. 5. Effects of CNI-1493 on LPS-induced CAT expression in
RAW 264.7 cells transfected with CAT-TNF constructs. CNI-1493 (1juM) was added to transfected RAW 264.7 cells for 1 hr prior to
addition of LPS at 1 jtg/ml or to uninduced controls as indicated. CAT
assay was performed on all transfected cells 4 hr after addition of LPS.
Results shown are representative of three experiments. Data are
expressed as the percentage of total CAT conversion.
translation of membrane 26-kDa TNF, which is normally
stimulated by LPS. CNI-1493 did not inhibit early nuclear
translocation of NF-KB after LPS stimulation (Fig. 3) and
thereby enabled significant increases of TNF mRNA, as
normally occurs after LPS stimulation (Fig. 2). The trans-
lation inhibition was observed to be dependent upon both
the 3' and 5' UTR elements of the TNF mRNA (Fig. 5). We
have previously shown that inhibition of TNF synthesis is
specific, because total cellular synthesis of RNA and protein
were unaffected by quantities of CNI-1493 that effectively
suppress TNF synthesis (3).
Previous work suggests that after macrophage activation,
discrete signaling pathways regulate the p38 MAP kinase-
dependent increases of TNF translation and the NF-KB-
dependent enhancement of TNF transcription (Fig. 1). Raf-1
activation has been implicated in the stimulation of an NF-KB
pathway in NIH 3T3 cells, but this pathway has not been
confirmed in monocyte/macrophages (8, 9). It is possible that
these signaling pathways diverge upstream of MEKK, the raf-1
homolog implicated in activation of JNK/p38 MAP kinase
family (5-7). The present results place the TNF-suppressive
activity of CNI-1493 in the p38 cascade because it inhibits
translation of the 26-kDa prohormone but does not inhibit the
translocation of NF-KB. Although the molecular target of
CNI-1493 remains unproved, the inhibitory effects of CNI-
1493 are not restricted to LPS-activated signaling pathways
because it suppressed TNF synthesis in monocytes activated by
exposure to TSST-1 (3), a stimulating agent that is indepen-
dent of LPS. Thus, the target of CNI-1493 may represent a
shared signaling point where LPS- and TSST-induced cascades
converge. Finally, it will be of interest to determine whether
the site of action is proximal or distal to p38 MAP kinase and
whether CNI-1493 can inactivate other members of the p38
MAP kinase cascade (e.g., cdc42, MEKK, and MKK3/MKK4)(5-7).
TNF occupies a proximal position in amplifying the proin-
flammatory cytokine cascade in LPS-activated macrophages.
For instance, neutralization of TNF with monoclonal anti-
body during overwhelming infection suppressed subsequent
increases of serum IL-1 and IL-6 despite persistent bacte-
remia (28). It is plausible that by inhibiting TNF synthesis,
CNI-1493 might prevent subsequent release of these sec-
ondary cytokines. In support of this hypothesis, we previ-
ously showed that CNI-1493 inhibited proinflammatory cy-
tokines (including IL-1, IL-6, MIP-la, MIP-1,3), iNOS, and
cytokine-inducible L-arginine transporter functions in LPS-
stimulated macrophages (2, 3). It will be of interest to
determine whether CNI-1493 suppressed these proinflam-
matory responses as an indirect consequence of TNF block-
ade or by a direct effect that suppressed a shared regulatory
mechanism common to these proinflammatory mediators.
CNI-1493 is also an effective macrophage cytokine suppres-
sor in the presence of IFN-y, suggesting that it will retain its
effectiveness in clinical conditions where IFN-y is ubiquitous(29). Because IFN-y can override the suppression of TNF in
the C3H/HeJ mice, which normally fail to produce TNF in
response to LPS, it will be of interest to use CNI-1493 to
further characterize the molecular basis for this genetic
defect (29, 30). It is hoped that these studies will further
understanding of the mechanism of macrophage activation
and cytokine synthesis and lead to the development of
therapeutic strategies to prevent the manifestation of mac-
rophage-mediated disease.
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